YOLFTbeta
aTyr Pharma, Inc.

aTyr Pharma, Inc.

ATYR · NASDAQ · Healthcare / Biotechnology

6.11USD-0.10 (-1.69%)

Price History

Full chart

Market Stats

Previous Close6.21
Open6.24
Day Range5.96 – 6.54
52-Week Range0.282 – 1.12
Volume37.98K
Market Cap29.92M
P/E (TTM)0.00
Forward P/E0.00
EPS-0.63
Dividend Yield0.00%
Beta0.53
50-Day Avg0.4824
200-Day Avg0.6733

About

aTyr Pharma, Inc., a clinical stage biotechnology company, engages in the discovery and development of product candidates that translate tRNA synthetase biology into new therapies for fibrosis and inflammation in the United States. Its lead therapeutic candidate efzofitimod, a selective modulator of NRP2 that is in Phase 3 clinical trial for the treatment of pulmonary sarcoidosis; Phase 2 clinical trial to treat Sarcoidosis and systemic sclerosis- interstitial lung disease (ILDs); and treatment of other ILDs, such as chronic hypersensitivity pneumonitis (CHP) and connective tissue disease related ILD. The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase, which is in preclinical development for the treatment of fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. aTyr Pharma, Inc. was incorporated in 2005 and is headquartered in San Diego, California.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Sanjay S. Shukla M.D., M.S.
  • Employees58
  • Headquarters10240 Sorrento Valley Road, San Diego, CA, United States, 92121, USA
  • Websitehttps://atyrpharma.com

Leadership

  • Dr. Sanjay S. Shukla M.D., M.S.President, CEO & Director · b. 1972
  • Ms. Nancy E. Denyes Krueger J.D.General Counsel & Corporate Secretary · b. 1968
  • Ms. Ashlee DunstonDirector of Investor Relations & Corporate Communications

Financials

Income Statement

Currency: USD2012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue-------422.00K10.46M010.39M353.00K235.00K190.00K
Growth (%)--------+2377.49%-100.00%--96.60%-33.43%-19.15%
Cost of Revenue540.00K---900.00K713.00K746.00K14.05M17.29M1.30M1.70M2.74M1.54M1.55M
Gross Profit-540.00K----900.00K-713.00K-746.00K-13.63M-6.84M-1.30M8.69M353.00K235.00K-1.36M
Gross Margin--------3228.91%-65.38%-83.68%100.00%100.00%-717.37%
Operating Expense12.06M---58.44M46.43M32.07M9.35M9.07M32.71M55.09M55.27M68.15M76.26M
Operating Income-12.60M-19.54M-23.55M-47.62M-59.34M-47.15M-32.82M-22.98M-15.91M-34.02M-46.40M-54.92M-67.91M-77.63M
Operating Margin--------5445.02%-152.19%--446.79%-15557.79%-28899.57%-40856.32%
EBITDA-12.05M-18.83M-22.73M-45.35M-57.00M-46.43M-32.07M-22.34M-14.64M-32.47M-43.65M-47.66M-62.48M-72.56M
EBITDA Margin--------5294.55%-140.08%--420.26%-13500.28%-26588.09%-38192.11%
Net Income-17.61M-20.01M-24.35M-47.97M-57.85M-48.21M-34.52M-23.60M-16.22M-33.77M-45.34M-50.39M-64.02M-74.12M
Net Income Margin--------5593.13%-155.18%--436.53%-14274.50%-27243.83%-39009.47%
R&D7.75M13.83M16.78M34.50M44.25M30.07M20.39M14.05M17.29M23.26M42.81M42.29M54.37M60.22M
R&D as % of Total Revenue-------3328.91%165.38%-412.17%11981.02%23137.02%31694.21%
Interest Expense272.00K444.00K832.00K-----------

Balance Sheet

Currency: USD2012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets7.47M39.79M20.64M129.68M80.52M89.36M52.75M36.19M38.73M115.54M95.79M120.65M96.83M94.16M
Total Liabilities8.73M105.87M111.65M14.63M17.72M25.11M19.10M15.16M7.24M6.41M24.50M30.18M27.00M26.88M
Total Equity-1.28M-68.50M-91.01M115.05M62.80M64.25M33.65M21.19M31.65M109.30M71.46M90.66M70.02M67.48M
Cash3.67M36.46M13.90M53.02M38.39M21.09M22.96M9.21M16.95M2.34M9.98M22.54M11.05M10.74M
Total Debt4.54M6.89M10.28M5.14M9.54M19.73M16.03M11.73M2.24M1.38M11.53M15.10M13.28M12.03M
Net Debt867.00K-29.57M-3.62M-47.88M-28.85M-1.36M-6.93M2.52M-14.71M-958.00K1.55M-7.45M2.23M1.29M

Cash Flow

Currency: USD2012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-11.38M-17.31M-22.82M-36.80M-52.86M-42.36M-31.06M-20.01M-15.30M-33.08M-41.89M-33.22M-69.12M-61.99M
Investing Cash Flow-598.00K-644.00K-2.25M-71.99M33.53M-27.64M37.17M4.92M6.90M-91.57M47.24M-20.13M17.23M-5.05M
Financing Cash Flow1.66M50.74M2.51M147.92M4.70M52.70M-4.24M1.34M16.14M110.03M5.45M66.23M39.86M66.01M
Capital Expenditure598.00K644.00K249.00K664.00K600.00K1.31M594.00K79.00K202.00K192.00K1.64M4.21M65.00K77.00K
Free Cash Flow-11.98M-17.95M-23.07M-37.46M-53.46M-43.68M-31.66M-20.09M-15.50M-33.27M-43.53M-37.44M-69.18M-62.06M
FCF to OCF105.26%103.72%101.09%101.80%101.14%103.10%101.91%100.39%101.32%100.58%103.92%112.69%100.09%100.12%

Earnings

Report DateJun 19, 2015Aug 12, 2015Nov 10, 2015May 11, 2016Aug 10, 2016Nov 14, 2016Mar 17, 2017May 11, 2017Aug 14, 2017Nov 14, 2017Mar 19, 2018May 14, 2018Aug 14, 2018Nov 13, 2018Mar 25, 2019May 13, 2019Aug 14, 2019Nov 14, 2019Mar 26, 2020May 12, 2020Aug 13, 2020Nov 12, 2020Mar 23, 2021May 13, 2021Aug 10, 2021Nov 10, 2021Mar 14, 2022May 9, 2022Aug 15, 2022Nov 10, 2022Mar 9, 2023May 9, 2023Aug 9, 2023Nov 9, 2023Mar 14, 2024May 2, 2024Aug 13, 2024Nov 7, 2024Mar 12, 2025May 7, 2025Aug 7, 2025Nov 6, 2025Mar 5, 2026May 13, 2026Aug 7, 2026Nov 5, 2026
EPS Estimate--4.53-6.37-10.36-9.74-9.36--6.25-7.69-6.90-5.60-0.35-4.69-4.06-3.04-3.17-2.74-1.73-1.54-0.18-0.73-0.74-0.47-0.32-0.49-0.57-0.31-0.33-0.38-0.46-0.48-0.41-0.27-0.22-0.24-0.25-0.24-0.22-0.23-0.19-0.18-0.18-0.18-0.14-0.15-0.11
EPS Actual-5.44-10.36-6.72-9.52-9.10-8.12-7.42-7.84-7.14-6.02-5.46-5.04-4.90-3.36-2.94-2.52-1.80-1.47-1.540.25-0.69-0.68-0.47-0.51-0.64-0.42-0.31-0.44-0.44-0.46-0.26-0.29-0.22-0.20-0.25-0.23-0.23-0.23-0.18-0.17-0.22-0.26-0.14-0.11-0.11-
Surprise--128.70%-5.49%8.11%6.57%13.25%--25.44%7.15%12.75%2.50%-1340.00%-4.48%17.24%3.29%20.50%34.31%15.03%0.00%238.89%5.48%8.11%0.00%-59.38%-30.61%26.32%0.00%-33.33%-15.79%0.00%45.83%29.27%18.52%9.09%-4.17%8.00%4.17%-4.55%19.96%10.53%-22.22%-44.44%22.22%22.81%26.67%-
Timing-After-hoursAfter-hoursAfter-hoursAfter-hoursPre-market-After-hoursAfter-hoursAfter-hoursAfter-hours-After-hoursAfter-hours-After-hoursPre-marketAfter-hours-After-hoursAfter-hoursAfter-hours-After-hoursAfter-hoursAfter-hours-After-hoursAfter-hoursAfter-hours-After-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hours--After-hours

Key Statistics & Ratios

Market Cap29.92M
Enterprise Value-9.42M
Trailing P/E0.00
Forward P/E0.00
Price / Sales157.46
Price / Book0.75
EPS-0.63
Book Value0.497
Revenue (TTM)190.00K
Gross Profit (TTM)-46.90M
EBITDA-63.20M
Profit Margin0.00%
Operating Margin-33609.47%
Return on Equity-98.68%
Return on Assets-46.58%
Shares Outstanding98.09M
Shares Float97.74M
Beta0.53
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Strong Buy
Based on 11 analystsTarget 2.86
  • Strong Buy
    7
  • Buy
    4

Ownership Breakdown

Institutions
39.83%
Insiders
2.46%
Retail / Other
57.71%

Top Institutional Holders

  • FMR Inc
    14.71M14.99%
  • Federated Hermes Inc
    8.51M8.68%
  • BlackRock Inc
    6.44M6.57%
  • UBS Group AG
    3.87M3.94%
  • Vanguard Capital Management, LLC
    3.81M3.89%
  • GSA Capital Partners LLP
    3.45M3.52%
  • Geode Capital Management, LLC
    2.39M2.43%
  • State Street Corp
    1.75M1.79%
  • Two Sigma Investments LLC
    1.25M1.27%
  • Citadel Advisors Llc
    1.24M1.27%
  • Morgan Stanley - Brokerage Accounts
    1.23M1.25%
  • Susquehanna International Group, LLP
    866.74K0.88%
  • Northern Trust Corp
    711.11K0.72%
  • Millennium Management LLC
    656.05K0.67%
  • Vanguard Fiduciary Trust Co
    651.83K0.66%
  • Vanguard Portfolio Management, LLC
    569.23K0.58%

Top Fund Holders

  • Federated Hermes Kaufmann R
    4.37M4.45%
  • Federated Hermes Kaufmann Small Cap A
    4.06M4.14%
  • Vanguard MStar Total Stk Mkt Idx Invest
    2.65M2.70%
  • Fidelity Select Biotechnology
    1.75M1.79%

Stock Splits

  • Oct 29, 20261:40
  • Jul 1, 20191:14